Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Evaluation of an albumin-binding gadolinium contrast agent in multiple sclerosis.
Cognitive impairment differs between primary progressive and relapsing-remitting MS.
Cytomegalovirus and multiple sclerosis risk.
Neurovascular and Immuno-Imaging: From Mechanisms to Therapies. Proceedings of the Inaugural Symposium.
Fiber density index in the evaluation of the spinal cord in patients with multiple sclerosis.
Identification of a Selective RORγ Ligand That Suppresses T(H)17 Cells and Stimulates T Regulatory Cells.
Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients.
Insights into the channel gating of P2X receptors from structures, dynamics and small molecules.
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes.
Quantitative proteome profiling of CNS-infiltrating autoreactive CD4(+) cells reveals selective changes during experimental autoimmune encephalomyelitis.
Smoking increases the risk of multiple sclerosis in Queensland, Australia.
Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
Endurance training is feasible in severely disabled patients with progressive multiple sclerosis.
Molecular biomarkers of neurodegeneration.
Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors.
Neuronal MHC-I expression and its implications in synaptic function, axonal regeneration and Parkinson's and other brain diseases.
Several food items and multiple sclerosis: A case-control study in Ahvaz (Iran).
Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.
Preliminary evaluation of variable compliance joystick for people with multiple sclerosis.
SLAM-SAP Signaling Promotes Differentiation of IL-17-Producing T Cells and Progression of Experimental Autoimmune Encephalomyelitis.
Can we measure long-term treatment effects in multiple sclerosis?
Phase imaging in brain using SWIFT.
Status migrainosus as an initial presentation of multiple sclerosis.
Zinc sulphate: A reasonable choice for depression management in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial.
Aspirin Promotes Oligodendroglial Differentiation Through Inhibition of Wnt Signaling Pathway.
Pages
« first
‹ previous
…
419
420
421
422
423
424
425
426
427
…
next ›
last »